🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchCan we talk about how SLOW the FDA is Page 3

Can we talk about how SLOW the FDA is

KarenAZ_mom Mon, Apr 20, 2026 at 10:27 AM 38 replies 1,036 viewsPage 3 of 8
Dr.CardioMD
VIP Member
2,678
14,567
Dec 2023
Cleveland, OH
Apr 21, 2026 at 12:47 PM#11
anna.melb_AU said:
Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational…

Fair, and it stops being fair at the extremes. The middle of the range is well understood; the ends are where the honest answer is that nobody knows.

36 11kim_atl_prep, sarah_TO, wendy_avl and 33 others
Reply Quote Save Share Report
fiona_VT
Member
178
890
Dec 2024
Vermont
Apr 22, 2026 at 12:46 AM#12
pete_nash said:
Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals.

Thank you for spelling out the reasoning rather than just the conclusion. Printing the relevant bit and taking it with me.

35 10hans_munich, jason_sac26, chris_chi24 and 32 others
Reply Quote Save Share Report
wendy_avl
Member
245
1,123
Oct 2024
Asheville, NC
Apr 22, 2026 at 12:45 PM#13
anna.melb_AU said:
Propensity score matching studies and the trial evidence: when RCTs aren't available for a specific question, propensity score-matched observational…

I read this differently from anna.melb_AU, on substance rather than tone. Not convinced. The evidence being cited is consistent with the conclusion and also consistent with two other conclusions nobody has ruled out.

Last edited: Apr 22, 2026 at 6:45 PM
34 9TomTeleRx, DoseLogDan, SleepFixSam and 31 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
LabKate
Senior Member
2,678
11,234
Jan 2024
Oregon
Apr 23, 2026 at 12:44 AM#14

The figures, for anyone assembling their own picture. One practical note: write down what you did and when, before you need it. Reconstructing a timeline from memory three months later is how people end up unable to answer the one question that would have resolved it.

Last edited: Apr 23, 2026 at 3:44 AM
33 8emily_PDX, Dr.SleepRoch, laura_annarbor and 30 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Apr 23, 2026 at 12:43 PM#15

Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again.

32 7PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 29 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register